{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:30:40Z","timestamp":1775791840388,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>The association of prostate cancer and androgen deprivation therapy (ADT) use with the odds of developing mild cognitive impairment (MCI) was determined in men from the population-based Mayo Clinic Study of Aging (MCSA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The study included 2513 men (mean age of 73.1\u2009y) enrolled in the MCSA. A history of prostate cancer, ADT use, and length of ADT exposure before their first MCSA visit was abstracted using the Rochester Epidemiology Project medical records-linkage system. MCI was diagnosed at the baseline visit. Logistic regression was used to determine whether prostate cancer and ADT use was associated with odds of MCI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of the 2513 participants, 349 (13.9%) had a history of prostate cancer; among whom 99 (28.3%) were treated with ADT before MCSA enrollment. There were 382 (15.2%) with a diagnosis of MCI. In the univariate logistic regression models, prostate cancer (odds ratio, 1.50; 95% confidence interval, 1.12-2.00), and ADT exposure (odds ratio, 1.57; 95% confidence interval, 0.96-2.58) were associated with higher odds of MCI. These associations were greatly attenuated and not significant in multivariable models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Neither a diagnosis of prostate cancer nor ADT use was associated with odds of MCI in this cross-sectional population-based study.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/wad.0000000000000366","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T09:39:17Z","timestamp":1575970757000},"page":"118-121","source":"Crossref","is-referenced-by-count":7,"title":["Prostate Cancer, Use of Androgen Deprivation Therapy, and Cognitive Impairment"],"prefix":"10.1097","volume":"34","author":[{"given":"Hector J.","family":"Alonso Qui\u00f1ones","sequence":"first","affiliation":[{"name":"School of Medicine, University of Puerto Rico, San Juan, Puerto Rico"},{"name":"Mayo Clinic Alix School of Medicine and Center for Clinical and Translational Science"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Stish","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clinton","family":"Hagen","sequence":"additional","affiliation":[{"name":"Health Sciences Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald C.","family":"Petersen","sequence":"additional","affiliation":[{"name":"Health Sciences Research"},{"name":"Neurology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Mielke","sequence":"additional","affiliation":[{"name":"Health Sciences Research"},{"name":"Neurology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/cncr.20955","article-title":"Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma","volume":"103","author":"Shahinian","year":"2005","journal-title":"Cancer"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-20230922","first-page":"303","article-title":"Complications of androgen deprivation therapy: prevention and treatment","volume":"18","author":"Holzbeierlein","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1634\/theoncologist.8-5-474","article-title":"Andropause: symptom management for prostate cancer patients treated with hormonal ablation","volume":"8","author":"Thompson","year":"2003","journal-title":"Oncologist"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1200\/JCO.2014.60.1963","article-title":"Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison","volume":"33","author":"Gonzalez","year":"2015","journal-title":"J Clin Oncol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00520-014-2285-1","article-title":"Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"22","author":"McGinty","year":"2014","journal-title":"Support Care Cancer"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"e196562","DOI":"10.1001\/jamanetworkopen.2019.6562","article-title":"Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer","volume":"2","author":"Jayadevappa","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/ADR-180052","article-title":"No relationship of anti-androgens to Alzheimer\u2019s disease or cognitive disorder in the MedWatch Database","volume":"2","author":"Lehrer","year":"2018","journal-title":"J Alzheimers Dis Rep"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cncr.30320","article-title":"Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer","volume":"123","author":"Alibhai","year":"2017","journal-title":"Cancer"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1017\/S1478951507000442","article-title":"Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions","volume":"5","author":"Nelson","year":"2007","journal-title":"Palliat Support Care"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000115751","article-title":"The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics","volume":"30","author":"Roberts","year":"2008","journal-title":"Neuroepidemiology"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/archneur.1991.00530190071018","article-title":"The short test of mental status. Correlations with standardized psychometric testing","volume":"48","author":"Kokmen","year":"1991","journal-title":"Arch Neurol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","article-title":"Validity of the Trail Making Test as an indicator of organic brain damage","volume":"8","author":"Reitan","year":"1958","journal-title":"Percept Mot Skills"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13854049208401877","article-title":"Mayo\u2019s Older Americans Normative Studies: WAIS-R norms for ages 56 to 97","volume":"6","author":"Ivnik","year":"1992","journal-title":"Clin Neuropsychol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J Intern Med"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jalz.2017.04.012","article-title":"Association of cancer and Alzheimer\u2019s disease risk in a national cohort of veterans","volume":"13","author":"Frain","year":"2017","journal-title":"Alzheimers Dement"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000356498","article-title":"Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies","volume":"83","author":"Catala-Lopez","year":"2014","journal-title":"Psychother Psychosom"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"e1442","DOI":"10.1136\/bmj.e1442","article-title":"Inverse association between cancer and Alzheimer\u2019s disease: results from the Framingham Heart Study","volume":"344","author":"Driver","year":"2012","journal-title":"BMJ"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1212\/WNL.0b013e3181c91873","article-title":"Cancer linked to Alzheimer disease but not vascular dementia","volume":"74","author":"Roe","year":"2010","journal-title":"Neurology"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.23658","article-title":"Cognitive effects of hormone therapy in men with prostate cancer: a review","volume":"113","author":"Nelson","year":"2008","journal-title":"Cancer"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jamaoncol.2016.3662","article-title":"Association between androgen deprivation therapy and risk of dementia","volume":"3","author":"Nead","year":"2017","journal-title":"JAMA Oncol"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/andr.12187","article-title":"Androgen deprivation therapy did not increase the risk of Alzheimer\u2019s and Parkinson\u2019s disease in patients with prostate cancer","volume":"4","author":"Chung","year":"2016","journal-title":"Andrology"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/JCO.2016.69.6203","article-title":"Androgen deprivation therapy and the risk of dementia in patients with prostate cancer","volume":"35","author":"Khosrow-Khavar","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Alzheimer Disease &amp; Associated Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WAD.0000000000000366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:29:58Z","timestamp":1695428998000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/WAD.0000000000000366"}},"subtitle":["A Population-based Study"],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/wad.0000000000000366","relation":{},"ISSN":["0893-0341"],"issn-type":[{"value":"0893-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,9]]}}}